Harrow (NASDAQ:HROW) Shares Down 4.9% - What's Next?

Key Points

• Harrow, Inc. shares dropped 4.9% to $38.07, with a significant decline in trading volume at 227,088 shares, compared to an average of 477,975 shares.
• Analysts maintain a positive outlook on Harrow, with seven rating it a "buy" and an average target price of $64.67.
• In its last quarter, Harrow reported an EPS of $0.24, exceeding expectations but with a slight revenue miss at $63.74 million against estimates of $64.23 million.

Harrow, Inc. (NASDAQ:HROW - Get Free Report)'s share price traded down 4.9% during trading on Friday . The stock traded as low as $37.70 and last traded at $38.07. 227,088 shares changed hands during mid-day trading, a decline of 52% from the average session volume of 477,975 shares. The stock had previously closed at $40.01.

Analyst Upgrades and Downgrades

HROW has been the topic of a number of analyst reports. HC Wainwright boosted their target price on shares of Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Cantor Fitzgerald began coverage on Harrow in a report on Friday, July 11th. They set an "overweight" rating and a $76.00 price objective on the stock. Zacks Research upgraded Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. William Blair assumed coverage on Harrow in a research report on Tuesday, June 10th. They set an "outperform" rating on the stock. Finally, BTIG Research increased their price target on shares of Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $64.67.

Harrow Stock Performance

The firm has a market cap of $1.41 billion, a P/E ratio of -152.92 and a beta of 0.41. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The stock has a 50 day moving average of $33.62 and a 200 day moving average of $29.05.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The firm had revenue of $63.74 million for the quarter, compared to analysts' expectations of $64.23 million. Harrow has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Harrow, Inc. will post -0.53 EPS for the current year.

Institutional Investors Weigh In On Harrow

Several institutional investors and hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Harrow by 89.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company's stock worth $2,078,000 after purchasing an additional 29,262 shares during the period. GAMMA Investing LLC lifted its stake in shares of Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock valued at $1,670,000 after buying an additional 6,027 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Harrow by 7.5% during the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company's stock valued at $10,705,000 after buying an additional 22,266 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after buying an additional 1,462 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Harrow by 8.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,076 shares of the company's stock valued at $640,000 after buying an additional 1,428 shares in the last quarter. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.